Media Coverage

Charles River buys Celsis for $212M

07/10/2015

The acquisition of Celsis International Ltd. complements Charles River Endotoxin and Microbial Detection’s (EMD) position as a leading provider of rapid endotoxin testing and bacterial identification for biopharmaceutical manufacturing, and creates the most comprehensive solution for rapid quality control testing of biopharmaceutical and consumer products.

Charles River spends $212M to Beef Up its Microbial Testing

07/09/2015

Charles River is absorbing Celsis, a Chicago-headquartered company that tests drugs and consumer products for contamination. Celsis works with pharma, beauty companies and the food industry, touting itself as a provider of rapid testing systems that allow clients to quickly get their products onto the market.

Why Charles River Labs spent $212M on a Bacteria Detection Company

07/09/2015

Charles River Labs announced Thursday that it had signed an agreement to acquire the bacteria detection company Celsis International Ltd. for $212 million. This acquisition will strengthen the Wilmington company’s market position in testing the safety of drugs and consumer products.

From Crab to Lab

06/23/2015

The Atlantic horseshoe crab and Charles River have mutually benefitted from one another for the last thirty years. In a recent article, John Dubczak, General Manager of Endotoxin and Microbial Detection, spoke about the value of the horseshoe crab and the efforts that Charles River has undergone in order to protect and preserve this natural resource.

The Rise of Syngeneic Models in Cancer Immunotherapy

06/17/2015

With cancer immunotherapy becoming a major focus of oncology research over the past several years, the next blockbuster drug will likely target the immune system. By exploiting model systems, such as syngeneic tumors, and identifying the next major variable associated with immunologically driven elimination of tumor cells, the promise of new immunotherapies can be realized.

The New Paradigm in Cardiac Toxicity Testing

06/04/2015

The Comprehensive in vitro Proarrhythmia Assay (CiPA) initiative came about after the realization that the current cardiac toxicity testing paradigm is too conservative, keeping potentially beneficial drugs off the market and away from patients who need them. At the same time, current methods are relatively poor predictors of drug-induced cardiac arrhythmias.

Displaying results 1-10 (of 64)
 |<  < 1 - 2 - 3 - 4 - 5 - 6 - 7  >  >|